By Nanobiotix
We believe that radiotherapy-activated NBTXR3 has the potential to transform the standard of care in cancer treatment. In 2019, NBTXR3 obtained its first European CE marking for the treatment of locally advanced soft tissue sarcoma in 27 European countries under the brand name Hensify®. NBTXR3 is currently being evaluated in 14 clinical trials across several different indications, including head and neck cancer, non-small cell lung cancer, and pancreatic cancer. Today, our resources are primarily devoted to the continued global development and indication expansion of NBTXR3. Our global clinical trials and successful indication expansion reveal the potential of NBTXR3 across markets, and our existing collaborations enable our candidate to reach patients facing cancer around the world. NANORAY-312, our phase 3 clinical trial for HNSCC, continues to build momentum, with active sites in the United States, Europe, and Asia. We remain focused on expanding the trial’s site footprint, driving patient recruitment, and preparing for milestone reporting.
